30 results on '"Katragadda, Madan"'
Search Results
2. A T cell receptor β chain–directed antibody fusion molecule activates and expands subsets of T cells to promote antitumor activity
3. 804 Anti-tumor effect of a novel Vβ TCR-targeting bifunctional agent in combination with anti-PD1 in checkpoint refractory murine lung cancer models
4. Supplementary Data from Development of Highly Optimized Antibody–Drug Conjugates against CD33 and CD123 for Acute Myeloid Leukemia
5. 1392 An atypical central memory like phenotype can be induced in human T cells by Innate TCRαβ engagement
6. Development of Highly Optimized Antibody–Drug Conjugates against CD33 and CD123 for Acute Myeloid Leukemia
7. Discovery and optimization of a novel anti-GUCY2c x CD3 bispecific antibody for the treatment of solid tumors
8. Expression of compstatin in Escherichia coli: Incorporation of unnatural amino acids enhances its activity
9. Thermal destabilization of rhodopsin and opsin by proteolytic cleavage in bovine rod outer segment disk membranes
10. Anti-PDGF-B monoclonal antibody reduces liver fibrosis development
11. Thermodynamic Studies on the Interaction of the Third Complement Component and Its Inhibitor, Compstatin
12. A soluble peripherin/Rds C-terminal polypeptide promotes membrane fusion and changes conformation upon membrane association
13. Assembly of a Polytopic Membrane Protein Structure from the Solution Structures of Overlapping Peptide Fragments of Bacteriorhodopsin
14. Solution structure of the loops of bacteriorhodopsin closely resembles the crystal structure
15. Abstract 935: Generation and preclinical characterization of CD123-CPI antibody-drug conjugate (ADC)
16. Changes in complementarity-determining regions significantly alter IgG binding to the neonatal Fc receptor (FcRn) and pharmacokinetics
17. Abstract 3095: The development of CPI as a novel, next-generation DNA-targeting payload for ADCs
18. Changes in complementarity-determining regions significantly alter IgG binding to the neonatal Fc receptor (FcRn) and pharmacokinetics.
19. Case studies and future applications in development
20. Trial START-001: A phase 1/2 study of STAR0602, a first-in-class, selective T cell receptor (TCR)-targeting, bifunctional antibody-fusion molecule, as monotherapy in patients with antigen-rich tumors post checkpoint inhibitor (CPI) treatment.
21. Electrostatic Modeling Predicts the Activities of Orthopoxvirus Complement Control Proteins1
22. Lipid and Detergent Effects on the Kinetic Stability of the GPCR, Rhodopsin
23. Preclinical studies of PF-04849285, an interferon-α8 fusion protein for the treatment of HCV
24. Hydrophobic Effect and Hydrogen Bonds Account for the Improved Activity of a Complement Inhibitor, Compstatin
25. Electrostatic Modeling Predicts the Activities of Orthopoxvirus Complement Control Proteins
26. Design and NMR Characterization of Active Analogues of Compstatin Containing Non-Natural Amino Acids
27. Preclinical Studies of Pf-04849285, An Interferon-a8 Fusion Protein for the Treatment of HCV
28. Structure–activity-based design of potent compstatin analogs
29. Structure of complement component C3b
30. Design and NMR characterization of active analogues of compstatin containing non-natural amino acids.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.